Arstasis

Arstasis is a company based in Fremont, California, specializing in medical devices. The company employs 23 individuals and generates approximately $51.5 million in annual revenue. Arstasis develops and manufactures AXERA® Access, a groundbreaking technology that enables self-sealing access in procedures. AXERA® Access utilizes the patient's own femoral artery wall to create a secure opening, eliminating the need for implants. This method offers numerous benefits, including significantly reduced manual compression time, allowing for faster patient recovery and mobilization. A key differentiator of AXERA® Access is its implant-free design. By relying on the patient's natural tissue for closure, the technology eliminates the risk of complications associated with implant materials. Studies such as the RECITAL trial have demonstrated the effectiveness of AXERA® Access, showing a substantial decrease in manual compression time, enabling patients to be elevated to a 45-degree angle within 15-30 minutes of hemostasis and ambulating within 1 to 2 hours. For more information about Arstasis and AXERA® Access, please visit their website at arstasis.com.